Bio-Path Holdings Inc

Good morning, ladies and gentlemen, and welcome to the BioPath Holdings first quarter 2020 earnings conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Will O'Connor of Stern Investor Relations. Please proceed.

Thank you, Operator. Welcome to the BioPath Holdings conference call and webcast to review the company's first quarter 2020 earnings results and to provide an update on recent pipeline and corporate developments. Earlier, we issued a press release which outlines the topics that we plan to discuss on today's call. The release is available at biopathholdings.com. With me today from Biopath are President and CEO Peter Nielsen and Senior Vice President of Finance, Accounting and Administration, Anthony Price. Before we begin, I'd like to remind you that today's discussion will contain four looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we urge you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Biopath CEO, Peter Nielsen.

Thanks, Will. Good morning, everyone, and thank you for joining us today, particularly during these challenging and unprecedented times. I hope this finds all of you and your families well and safe. Despite the extensive social impact of COVID-19 pandemic, I am pleased to report that here at BioPath, we have taken every precaution possible to safeguard the health and safety of our employees and clinical trial participants. And that even in these difficult times, we remain on track to achieve our clinical milestones this year. The considerable progress we made throughout 2019 continues to serve as the foundation for us to advance our clinical pipeline toward important inflection points in 2020. As it stands now, we are continuing to advance our innovative RNAi nanoparticle programs, built on our de-enabilized platform to treat patients suffering with a variety of life-threatening cancer indications. Let me begin with a review of our de-enabilized platform and its key features. As you know, the de-enabilized platform is our proprietary antisense RNAI nanoparticle technology, which we use for the creation of nucleic acid therapeutics. De-enabilized therapeutics integrate with the cellular membrane because of their unique structure, allowing the antisense drug to be delivered to the disease cells with high uptake into the cell via incorporation into lipid layers.